Health-Economic Evaluation of the Disease Management Program for Chronic Obstructive Pulmonary Disease in Germany

德国慢性阻塞性肺疾病疾病管理计划的健康经济评估

• 批准号: 274141286
• 负责人: Professor Dr. Jonas Schreyögg
• 金额: --
• 依托单位: Lehrstuhl Health Care Management
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2015
• 资助国家: 德国
• 起止时间: 2014-12-31 至 2017-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/274141286?language=en
• 关键词: Health; Economic; Evaluation; Disease; Management

Over the last decade, the management of COPD in Germany has gradually changed. Disease management programs (DMP) have been proposed and implemented in patients with COPD. The aim of these programs was to modify treatment patterns, thereby improving outcomes of care whilst increasing the efficient use of scarce health care resources, or even generating cost savings. Internationally, a number of studies evaluated interventions that follow the disease management approach for the management of COPD. However, the design of these interventions is highly heterogeneous and not comparable to the German setting. While there have been numerous studies evaluating DMP type 2 Diabetes in Germany, including four studies gathering retrospective claims data from sickness funds, little evidence is available for all other German DMPs, including DMP COPD.Being the first study of its kind in the German healthcare context, the primary aim of this study is to compare the cost-effectiveness of DMP COPD with standard care for COPD over a time period of 3 years. To do so, we will retrospectively evaluate administrative claims data from the BARMER/GEK, a large German sickness fund with 8.6 million insured. Patients will be included into the study (a) if with at least one inpatient ICD-10 main diagnosis for COPD of J41.-, J42.-, J43.- or J44.-, (b) if with at least one inpatient main diagnosis of J12.- to J18.- and J20.- to J22.- in combination with a secondary diagnosis for COPD of J41.-, J42.-, J43.-, or J44.-, or (c) if with at least two outpatient diagnoses for COPD of J41.-, J42.-, J43.-, or J44.- within 180 days in the year 2010. The patient cohort will then be divided into an intervention group (i.e., the patient is a member in a DMP COPD) and into a control group. We will follow-up patients for 3 years until 2013 while using data from 2008 to 2010 for risk-adjustment. Effectiveness will be measured in terms of mortality, number of (emergency) hospital visits and ability to work. Costs will be measured from the payer perspective.As the use of observational data may result in treatment selection bias, a two-step risk-adjustment will be applied. First, propensity score matching will reduce heterogeneity between the intervention and control group including socio-demographic variables, COPD specific variables and generic comorbidity measures (Elixhauser-Score). Second, based on the matched sample, regression models for each outcome are estimated, i.e. a Cox proportional hazard model for mortality, count data models for the number of (emergency) hospital visits and for the days incapable to work, and a gamma models for costs.The results might demonstrate the success of structured care programs which can be used to encourage active participation and enrolment by patients and to stimulate the participation of providers. Using a large dataset, the study might also be able to identify patient subgroups that benefit most from DMP COPD.

在过去的十年中，德国COPD的管理逐渐发生了变化。疾病管理计划（Disease Management Programs，简称CDC）已在COPD患者中提出并实施。这些计划的目的是修改治疗模式，从而改善护理结果，同时提高稀缺医疗资源的有效利用，甚至节省成本。在国际上，许多研究评估了遵循疾病管理方法管理COPD的干预措施。然而，这些干预措施的设计差异很大，与德国的情况不可比较。虽然在德国有许多研究评估了慢性2型糖尿病，包括四项从疾病基金收集回顾性索赔数据的研究，但几乎没有证据可用于所有其他德国DMP，包括慢性COPD。作为德国医疗保健背景下的第一项此类研究，本研究的主要目的是在3年的时间内比较慢性阻塞性肺疾病（COPD）常规治疗与标准治疗的成本效益。为此，我们将回顾性地评估来自BARMER/GEK的行政索赔数据，这是一家拥有860万保险人的大型德国疾病基金。患者将被纳入研究（a）如果至少有一次住院ICD-10主要诊断为COPD J 41.-，J42-，J43或者J 44 (b)如果至少有一个住院主要诊断为J12。到J18 J20-到J22结合J 41.-COPD的次要诊断，J42-，J43-，或者J 44或（c）如果具有至少两个J 41.-的COPD门诊诊断，J42-，J43-，或者J 44 2010年180天内。然后将患者群组分为干预组（即，该患者是COPD患者中的一员）和对照组。我们将对患者进行3年随访，直至2013年，同时使用2008年至2010年的数据进行风险调整。将从死亡率、（急诊）医院就诊次数和工作能力方面衡量有效性。成本将从支付者的角度进行衡量。由于观察性数据的使用可能会导致治疗选择偏差，因此将应用两步风险调整。首先，倾向评分匹配将减少干预组和对照组之间的异质性，包括社会人口统计学变量、COPD特异性变量和一般合并症指标（Elixhauser评分）。其次，基于匹配的样本，估计每个结果的回归模型，即死亡率的考克斯比例风险模型，（急诊）医院就诊和无法工作的日子，结果可能证明结构化护理计划的成功，该计划可用于鼓励患者积极参与和登记，并刺激患者的健康。供应商的参与。使用大型数据集，该研究还可能能够确定从COPD中获益最多的患者亚组。